Trial Profile

A Phase 2 randomized, dose-blinded, active-controlled, dose-ranging clinical study of AL01211 in patients with Fabry disease

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 23 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AL 01211 (Primary)
Indications Fabry's disease
Focus Adverse reactions; Therapeutic Use
Sponsors AceLink Therapeutics

Most Recent Events

21 Jun 2023 According to an AceLink Therapeutics media release, company announced that they have received clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial of its lead program, AL1211.
11 May 2023 New trial record
08 May 2023 According to an AceLink Therapeutics media release, AL01211, enters into two Phase 2 clinical trials later this year

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com